A fundamental analysis of Sun Pharmaceutical Industries Ltd. (SUNPHARMA) covering revenue trends, profitability, valuation, and shareholding patterns.
Sun Pharma Revenue Trend
For FY2026, Sun Pharmaceutical Industries Ltd. recorded revenue of ₹58,462 Cr. That's 11.2% higher than the ₹52,578 Cr it brought in during FY2025.
Stepping back, the 10-year revenue CAGR of 7.5% shows Sun Pharmaceutical Industries Ltd. has been growing at a moderate, sustainable pace.
Sun Pharmaceutical Industries Ltd.'s ₹58,462 Cr revenue base puts it in the major bracket among pharmaceuticals companies in India.
Sun Pharmaceutical Industries Ltd. has posted revenue growth for 8 consecutive years — that's a sustained trend, not a one-off.
| Year | Revenue | YoY % |
|---|---|---|
| FY2026 | ₹58,462 Cr | +11.2% |
| FY2025 | ₹52,578 Cr | +8.4% |
| FY2024 | ₹48,497 Cr | +10.5% |
| FY2023 | ₹43,886 Cr | +13.5% |
| FY2022 | ₹38,654 Cr | — |
View Sun Pharmaceutical Industries Ltd.'s full 10-year revenue trend with CAGR analysis →
Sun Pharma Profitability
Profitability strengthened with net income of ₹11,509 Cr in FY2026, 5.3% higher than FY2025.
The company's net margin contracted to 19.7% in FY2026 from 20.8% in FY2025.
Earnings per share (diluted) were ₹47.80 in FY2026, up from ₹45.60.
Is Sun Pharma Undervalued
Sun Pharmaceutical Industries Ltd. shares are currently trading at ₹1,963.50.
Craytheon calculates intrinsic value using the P/E Ratio, DCF, and EPS Growth models. All three appear in the Valuation Models cards below.
Valuation Models
Sun Pharma Shareholding Pattern
A stable promoter holding of 54.5% over 4 quarters suggests the management group is comfortable with its position.
FII ownership stands at 14.5%, down from the 16.6% recorded a year ago.
Domestic investors held 22.2% of the company as of June 2026, up year-over-year from 20.2%.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Jun 2026 | 54.5% | 14.5% | 22.2% | 8.8% |
| Mar 2026 | 54.5% | 15.9% | 21.1% | 8.5% |
| Dec 2025 | 54.5% | 16.1% | 20.8% | 8.6% |
| Sep 2025 | 54.5% | 16.6% | 20.2% | 8.7% |
Track quarterly shareholding changes for Sun Pharmaceutical Industries Ltd. →
Sun Pharma Balance Sheet
Proportional view as of 3 Aug 2026. Hover blocks for details.
Assets
Liabilities & Equity
In FY2026, the total asset base came in at ₹1,087.85B, up 18.1% YoY from ₹921.01B.
Cash & ST Investments accounts for 28.2% of the total, ahead of Intangibles & Goodwill (21.5%) and Receivables (14.3%).
Capital structure: 77.1% equity, 4.3% debt, 18.6% operating liabilities. Over the year, debt is up 95.9% and equity is up 15.7%.
Balance sheet composition — FY 2026
| Category | Value |
|---|---|
| Cash & ST Investments | 307.04B |
| Receivables | 155.10B |
| Inventories | 114.93B |
| Property, Plant & Equipment | 124.95B |
| Investments | 37.89B |
| Intangibles & Goodwill | 233.79B |
| Other Assets | 114.16B |
| Category | Value |
|---|---|
| Equity | 838.80B |
| Short-term Debt | 42.34B |
| Long-term Debt | 3.93B |
| Trade Payables | 73.34B |
| Other Liabilities | 129.44B |
Sun Pharma at a Glance
Here's the bottom line on Sun Pharmaceutical Industries Ltd. (SUNPHARMA) based on the latest available financials.
Revenue of ₹58,462 Cr in FY2026, up 11.2% year-over-year.
Long-term revenue has been compounding at 7.5% annually over 10 years.
The company is profitable, with a net margin of 19.7% and net income of ₹11,509 Cr.
Unlock Full Analysis
There's more to the story. Craytheon's full profile for Sun Pharmaceutical Industries Ltd. includes three valuation models, decade-long financials, and insider activity.